BACKGROUND: We present a simulation model that predicts U.S. breast cancer mortality trends from 1975 to 2000 and quantifies the impact of screening mammography and adjuvant therapy on these trends. This model was developed within the Cancer Intervention and Surveillance Network (CISNET) consortium. METHOD: A Monte Carlo simulation is developed to generate the life history of individual breast cancer patients by using CISNET base case inputs that describe the secular trend in breast cancer risk, dissemination patterns for screening mammography and adjuvant treatment, and death from causes other than breast cancer. The model generates the patient's age, tumor size and stage at detection, mode of detection, age at death, and cause of death (breast cancer versus other) based in part on assumptions on the natural history of breast cancer. Outcomes from multiple birth cohorts are summarized in terms of breast cancer mortality rates by calendar year. RESULT: Predicted breast cancer mortality rates follow the general shape of U.S. breast cancer mortality rates from 1975 to 1995 but level off after 1995 as opposed to following an observed decline. Sensitivity analysis revealed that the impact adjuvant treatment may be underestimated given the lack of data on temporal variation in treatment efficacy. CONCLUSION: We developed a simulation model that uses CISNET base case inputs and closely, but not exactly, reproduces U.S. breast cancer mortality rates. Screening mammography and adjuvant therapy are shown to have both contributed to a decline in U.S. breast cancer mortality.
BACKGROUND: We present a simulation model that predicts U.S. breast cancer mortality trends from 1975 to 2000 and quantifies the impact of screening mammography and adjuvant therapy on these trends. This model was developed within the Cancer Intervention and Surveillance Network (CISNET) consortium. METHOD: A Monte Carlo simulation is developed to generate the life history of individual breast cancerpatients by using CISNET base case inputs that describe the secular trend in breast cancer risk, dissemination patterns for screening mammography and adjuvant treatment, and death from causes other than breast cancer. The model generates the patient's age, tumor size and stage at detection, mode of detection, age at death, and cause of death (breast cancer versus other) based in part on assumptions on the natural history of breast cancer. Outcomes from multiple birth cohorts are summarized in terms of breast cancer mortality rates by calendar year. RESULT: Predicted breast cancer mortality rates follow the general shape of U.S. breast cancer mortality rates from 1975 to 1995 but level off after 1995 as opposed to following an observed decline. Sensitivity analysis revealed that the impact adjuvant treatment may be underestimated given the lack of data on temporal variation in treatment efficacy. CONCLUSION: We developed a simulation model that uses CISNET base case inputs and closely, but not exactly, reproduces U.S. breast cancer mortality rates. Screening mammography and adjuvant therapy are shown to have both contributed to a decline in U.S. breast cancer mortality.
Authors: Jeanne S Mandelblatt; Natasha K Stout; Clyde B Schechter; Jeroen J van den Broek; Diana L Miglioretti; Martin Krapcho; Amy Trentham-Dietz; Diego Munoz; Sandra J Lee; Donald A Berry; Nicolien T van Ravesteyn; Oguzhan Alagoz; Karla Kerlikowske; Anna N A Tosteson; Aimee M Near; Amanda Hoeffken; Yaojen Chang; Eveline A Heijnsdijk; Gary Chisholm; Xuelin Huang; Hui Huang; Mehmet Ali Ergun; Ronald Gangnon; Brian L Sprague; Sylvia Plevritis; Eric Feuer; Harry J de Koning; Kathleen A Cronin Journal: Ann Intern Med Date: 2016-01-12 Impact factor: 25.391
Authors: Jeanne S Mandelblatt; Kathleen A Cronin; Donald A Berry; Yaojen Chang; Harry J de Koning; Sandra J Lee; Sylvia K Plevritis; Clyde B Schechter; Natasha K Stout; Nicolien T van Ravesteyn; Marvin Zelen; Eric J Feuer Journal: Breast Date: 2011-10 Impact factor: 4.380
Authors: Diego Munoz; Aimee M Near; Nicolien T van Ravesteyn; Sandra J Lee; Clyde B Schechter; Oguzhan Alagoz; Donald A Berry; Elizabeth S Burnside; Yaojen Chang; Gary Chisholm; Harry J de Koning; Mehmet Ali Ergun; Eveline A M Heijnsdijk; Hui Huang; Natasha K Stout; Brian L Sprague; Amy Trentham-Dietz; Jeanne S Mandelblatt; Sylvia K Plevritis Journal: J Natl Cancer Inst Date: 2014-09-24 Impact factor: 13.506
Authors: Marc D Ryser; Mathias Worni; Elizabeth L Turner; Jeffrey R Marks; Rick Durrett; E Shelley Hwang Journal: J Natl Cancer Inst Date: 2015-12-17 Impact factor: 13.506
Authors: Bronislava M Sigal; Diego F Munoz; Allison W Kurian; Sylvia K Plevritis Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-05-03 Impact factor: 4.254
Authors: Allison W Kurian; Diego F Munoz; Peter Rust; Elizabeth A Schackmann; Michael Smith; Lauren Clarke; Meredith A Mills; Sylvia K Plevritis Journal: J Clin Oncol Date: 2012-01-09 Impact factor: 44.544
Authors: Jeanne S Mandelblatt; Kathleen A Cronin; Stephanie Bailey; Donald A Berry; Harry J de Koning; Gerrit Draisma; Hui Huang; Sandra J Lee; Mark Munsell; Sylvia K Plevritis; Peter Ravdin; Clyde B Schechter; Bronislava Sigal; Michael A Stoto; Natasha K Stout; Nicolien T van Ravesteyn; John Venier; Marvin Zelen; Eric J Feuer Journal: Ann Intern Med Date: 2009-11-17 Impact factor: 25.391